A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.
about
Preventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology GuidelineCurrent status of human papillomavirus vaccinesSafety of human papillomavirus vaccines in healthy young women: a meta-analysis of 24 controlled studiesEffect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates.Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years.Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteinsRegression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine.Vaccine adjuvant materials for cancer immunotherapy and control of infectious diseaseEfficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.Second-generation prophylactic HPV vaccines: successes and challenges.Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study.Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® VaccineNaturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial.Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study.Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine.A DNA vaccine encoding mutated HPV58 mE6E7-Fc-GPI fusion antigen and GM-CSF and B7.1.HPV prophylactic vaccination in males improves the clearance of semen infection.Naturally Occurring Major and Minor Capsid Protein Variants of Human Papillomavirus 45 (HPV45): Differential Recognition by Cross-Neutralizing Antibodies Generated by HPV Vaccines.The DE and FG loops of the HPV major capsid protein contribute to the epitopes of vaccine-induced cross-neutralising antibodies.Spotlight on the 9-valent HPV vaccine.Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities.Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts.Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs.Prevalence of Human Papillomavirus infection among Chilean women from 2012 to 2016.Current status and future prospects for human papillomavirus vaccines.A novel trivalent HPV 16/18/58 vaccine with anti-HPV 16 and 18 neutralizing antibody responses comparable to those induced by the Gardasil quadrivalent vaccine in rhesus macaque model.JC polyomavirus mutants escape antibody-mediated neutralization.Human papillomavirus 16L1-58L2 chimeric virus-like particles elicit durable neutralizing antibody responses against a broad-spectrum of human papillomavirus types.Naturally Occurring Single Amino Acid Substitution in the L1 Major Capsid Protein of Human Papillomavirus Type 16: Alteration of Susceptibility to Antibody-Mediated Neutralization.Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development.Combining agent based-models and virtual screening techniques to predict the best citrus-derived vaccine adjuvants against human papilloma virus.Reactogenicity of Cervarix and Gardasil human papillomavirus (HPV) vaccines in a randomized single blind trial in healthy UK adolescent females.Evaluation of Dried Blood Spots and Oral Fluids as Alternatives to Serum for Human Papillomavirus Antibody Surveillance.
P2860
Q26749285-30226343-4E44-4781-B1BA-667EAB91A9F1Q26991640-C6EA454D-EF3D-4A0D-B53E-197D16B93B34Q33891821-D4102926-BC29-47A4-B43C-1CCD916DF1ECQ34149348-62C6038F-9080-421F-B95E-ED28641ABF2FQ34291136-BA284DA3-7E91-4BB6-A88B-13E279675A4BQ34492140-B7329B38-3765-4BCC-9F3D-4861EEC158A3Q34729962-E58ECC36-DF7C-46E1-A283-922A64317A8FQ35035612-1BC5581A-C289-4D7E-B5D9-1209BA1852B3Q35221177-6704EDBE-8D51-41DE-ADCA-CE1E561D0FFBQ35541886-52559125-8C5F-41E3-BEFF-5317FE3FE798Q35810353-2FC65A16-9806-4ED4-8CF7-01E53150A8A8Q35818648-CAE5081B-4B69-4E81-A80F-5FA83577ECF6Q35861286-35516A25-192A-4063-90FF-7363541F325BQ35886534-048E3CAF-ED10-467A-BDBC-343DE17389BEQ35886612-383EA795-0527-483E-9D0B-08D99A18DB94Q35886910-B6B4336D-7E42-49C7-96C5-E4A4BE374B5EQ35887542-4BB3C609-7F1B-46D8-B0B3-DF61321718D4Q36244253-AF3D26CE-DFF1-4DDB-ABD6-2E1BEF134E4BQ36252874-4F83D461-3B8C-4F9F-AC01-516E2D228866Q36736614-6383B348-20DF-40A0-97E1-C145CDE03E9CQ37526148-D5148709-77CC-4D72-B517-6E9F1FDCF19CQ37538132-2749E7E8-D288-4048-BAAA-D20BC8719C3BQ37671423-7468B67B-D989-4C3C-A070-762F57B509B9Q38229304-FF7E1B9F-3690-46BF-9F07-D3090690B9CCQ38255277-F444D52E-CF39-4137-82EA-700A63BFB16DQ38745367-C04E2AA3-2D48-4F76-99A9-F89CB6924E6FQ40056541-297CA5BD-50FD-4F91-9B0C-226F222E4B5FQ40129472-C3AC92C6-2F42-4608-9123-81B3F59A136CQ40984700-7F2B8A59-4A26-4FF7-89AC-AC8653F7C5E1Q41926367-919172A8-E24E-4268-8C36-6F0075FC8CFFQ41926483-3E7E6D44-F928-4364-B3A5-E1ACEC550C39Q47549756-43ED012A-8847-402E-B4B5-51F652654254Q47558629-0A5FF9ED-B027-4CFB-8219-6D4B7F357905Q50788444-BBBC7B4C-2D80-4250-A6E9-979CA8580644Q54216892-729AD554-F7EB-457C-9F57-AD1180410181
P2860
A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
A randomized, observer-blinded ...... cines in 12-15 year old girls.
@ast
A randomized, observer-blinded ...... cines in 12-15 year old girls.
@en
A randomized, observer-blinded ...... cines in 12-15 year old girls.
@nl
type
label
A randomized, observer-blinded ...... cines in 12-15 year old girls.
@ast
A randomized, observer-blinded ...... cines in 12-15 year old girls.
@en
A randomized, observer-blinded ...... cines in 12-15 year old girls.
@nl
prefLabel
A randomized, observer-blinded ...... cines in 12-15 year old girls.
@ast
A randomized, observer-blinded ...... cines in 12-15 year old girls.
@en
A randomized, observer-blinded ...... cines in 12-15 year old girls.
@nl
P2093
P2860
P1433
P1476
A randomized, observer-blinded ...... cines in 12-15 year old girls.
@en
P2093
Elizabeth Miller
Eve Draper
Kate Soldan
Nicholas Andrews
Pauline Waight
Rebecca Howell-Jones
Sara L Bissett
Simon Beddows
P2860
P304
P356
10.1371/JOURNAL.PONE.0061825
P407
P50
P577
2013-05-01T00:00:00Z